Phathom Pharmaceuticals heads into mid-June with short sellers holding their most aggressive stance in months — and the borrow market beginning to catch up.
Short interest is the headline story here. Bears have built their position to 14.8% of the free float, up 7.6% over the past month and nudging higher again this week. That's a meaningful accumulation by any measure, and the directional drift has been one-way: shorts added roughly 1.2 million shares between early May and mid-June. The ORTEX short score of 77.6 reflects that pressure — it has held in the upper-70s for the past two weeks without retreating, suggesting the bearish conviction is sticky rather than opportunistic.
The borrow market adds a wrinkle to that picture. Availability — the ratio of shares still available to lend against those already borrowed — has tightened sharply. It dropped from around 143% in late May to 75% now, meaning the lending pool is narrowing even as short interest keeps climbing. Cost to borrow jumped 42% this week alone to 0.75%, though in absolute terms it remains low. The combination is worth tracking: borrow is not yet stressed, but the direction of travel is clear. The 52-week tightest point was 24%, so there is headroom to tighten further. Options confirm a bias toward calls rather than puts — the put/call ratio is just 0.069, running slightly above its 20-day average of 0.060 but nowhere near alarming. This is not a market hedging defensively; it's one with a strong directional lean from the short side, uncontested by meaningful downside protection demand.
The Street, by contrast, is firmly constructive on PHAT. Seven analysts carry Buy ratings with an average price target of $23.70 against a current price of $10.43 — a gap that implies substantial upside on the bull case. HC Wainwright reiterated its Buy with a $26 target as recently as today. Barclays upgraded to Overweight in late March, lifting its target to $18. The tension between that analytical consensus and a 14.8% short float is the central debate: bulls point to accelerating VOQUEZNA prescription growth — up 28% in Q2 2025 to over 790,000 total fills — and a widening market estimate for novel GERD treatments. Bears focus on persistent quarterly losses, the $30 million net loss recorded in Q3 2025, and lingering concerns about an unfavorable FDA exclusivity ruling. Goldman Sachs sits alone on the sidelines at Neutral with a $5 target, though that target dates from May 2025 and may not reflect current commercial progress. Factor scores tilt toward the bull narrative on earnings momentum — PHAT ranks in the 93rd percentile for both 30-day and 90-day EPS momentum, and in the 91st for EPS surprise — but the short score rank of just 5 confirms that bearish positioning is intense relative to the broader universe.
Institutional ownership offers a more balanced read. The top holder, Frazier Life Sciences, holds 15.6% and stood pat in the most recent quarter. Millennium Management added nearly 1.9 million shares to reach a 5% stake — meaningful buying from a hedge fund known for quantitative and event-driven strategies. Invesco and BlackRock both added in the period, each picking up over 500,000 shares. Ensign Peak trimmed by 724,000 shares, providing the lone notable exit. The net picture is one of institutional holders broadly stable to slightly accumulating, which makes the high short interest look less like informed fundamental selling and more like a contested trade.
Earnings are next due August 6. Recent prints have generated modest moves: a 4.2% gain on the day after the May 19 report, and a 5.5% decline after the February release. The next print will be the one to watch, both for prescription growth trends and any update on the balance sheet runway — with shorts dug in at nearly 15% of float and borrow availability drifting tighter, the setup into that announcement will deserve a close look.
See the live data behind this article on ORTEX.
Open PHAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
